Coultreon Biopharma’s lead drug candidate, acquired from Galapagos, is a small molecule designed to selectively inhibit a novel immunology goal known as SIK3. The Collection A financing will help Part 2 scientific trials in psoriasis and ulcerative colitis.
The submit Immunology-Targeted Coultreon Provides $125M for Capsules That Pack the Punch of Injectable Biologics appeared first on MedCity Information.
